Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Can NervGen keep a lid on explosive news?

Speculation of early “evidence” of successful proof-of-concept human trials sparks stock rallies Trial volunteers taking a placebo are offered the real deal in a follow-up trial as a “reward” The company&Clo...
Knox Henderson | March 20, 2024 |

Buzz on the Bullboards: Good stocks with bad publicity

It was hedge fund legend Ray Dalio who said: “He who lives by the crystal ball will eat shattered glass.” Many stock markets may have seen a higher start to the year so far, but there is far from a universal sentiment across the sectors, with s...
Jonathon Brown | January 25, 2024 |

Pharmaceutical company treats bladder cancer with new tech

The following is a transcription of the above video, and The Market Herald Canada has edited it for clarity . Theralase Technologies Inc. (TSXV:TLT) , a clinical-stage pharmaceutical company, is currently developing an innovative, research-backed technology for the ...
Ryan Dhillon | January 8, 2024 |

Theralase is raising up to $5.3M to complete bladder cancer study

Theralase Technologies is announcing a brokered financing raise for up to C$5.3 million Proceeds of the financing will be used to further the Phase II Non-Muscle Invasive Bladder Cancer (NMIBC) clinical study Ruvidar is designed to destroy solid core tum...
Coreena Robertson | November 6, 2023 |

Buzz on the Bullboards: The calm before another September rally?

It’s the last leg of what looks like an end-of-month rally as investors try to make the most of August’s losses. Traders are neck-deep into a data-heavy week from company fiscal reports that could chart the hike path for interest rates. ...
Jonathon Brown | August 31, 2023 |

Why This Psychedelics Company is Focused on Weight Management

Psychedelics are transforming so many aspects of our everyday lives — from treating mental health conditions to weight management and obesity. Companies like NeonMind Biosciences ( CSE:NEON , OTCQB:NMDBD , Forum ) are at the forefront of this innovation ...
Jocelyn Aspa | May 4, 2022 |

A Company on a Mission to Revolutionize Mental Healthcare. Here’s How.

When Stockhouse Editorial last caught up with Cybin Inc. ( NEO.CYBN , NYSE: CYBIN , Forum ) back in October, our audience learned about a leading biotechnology company focused on researching and progressing psychedelic therapeutics by utilizing proprietary drug discover...
Dave Jackson | January 31, 2022 |

The Medical Device Co. That’s on the Cutting-Edge of Advancing Heart Disease Treatment

Back in early September , we introduced our Stockhouse audience to a unique play in the emerging medical tech space – Neovasc Inc. ( TSX: NVCN , OTCQB: NVCN , Forum ). The company develops, manufactures, and markets products for the rapidly growing cardiovascular marke...
Dave Jackson | November 29, 2021 |

Mersana Therapeutics Trades 60% Higher on Positive Phase 1 Ovarian Cancer Trial Data

Shares of Mersana Therapeutics reached a new 52-week high price after the company reported positive interim data from the expanded portion of its Phase 1 study of XMT-1536 for treatment of ovarian cancer. Clinical-stage biopharmaceutical company Mersana Therapeuti...
Streetwise Reports | May 28, 2020 |

Novavax Shares Rise 9% Upon Initiating Phase 1/2 COVID-19 Vaccine Clinical Trial

Novavax shares traded higher after the company reported it enrolled the first participants in its Phase 1 clinical study of NVX CoV2373. Novavax Inc. (NVAX:NASDAQ) , which focuses its efforts on developing next-generation vaccines to address infectious diseases, ye...
Streetwise Reports | May 27, 2020 |
1 2